Pentavalent

Bengaluru, India Founded: 2015 • Age: 11 yrs
Vaccines and research services for infectious diseases are provided.
Annual revenue $241,408 Latest available
Total funding $40,819 2 rounds
Employees - Tracked headcount
Investors 2 Known backers
Products 4 Services tracked
Competitors 10 Brand Intelligence

About Pentavalent

Pentavalent is a company based in Bengaluru (India) founded in 2015 by Bhavani PV and Soumya Paul. Pentavalent has raised $40.82 thousand across 2 funding rounds from investors including Bioinnovation Centre and Startup Karnataka. Pentavalent offers products and services including Antibodies, Antigens, Cytokines, and Enzymes. Pentavalent operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.

  • Headquarter Bengaluru, India
  • Founders Bhavani PV, Soumya Paul
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Pentavalent Bio Sciences Private Limited
  • Date of Incorporation 24 Feb, 2015
  • Jurisdiction Bangaluru, Karnataka, India
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Biotechnology, Genomics & Life Sciences Research Unlock Sub-Sector Unlock Segment
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $241.41 K (USD)
    356.01
    as on Mar 31, 2023
  • Net Profit
    $20.74 K (USD)
    300.13
    as on Mar 31, 2023
  • EBITDA
    $31.07 K (USD)
    222.19
    as on Mar 31, 2023
  • Total Equity Funding
    $40.82 K (USD)

    in 2 rounds

  • Latest Funding Round
    $40.82 K (USD), Seed

    Oct 19, 2020

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Pentavalent

Pentavalent offers a comprehensive portfolio of products and services, including Antibodies, Antigens, Cytokines, and Enzymes.

Product name locked
Category locked
Primary

Monoclonal antibodies for precise IVD testing applications

Product name locked
Category locked
Locked

Recombinant proteins tailored for diagnostics and research

Product name locked
Category locked
Locked

Signaling proteins for immune response diagnostics

Product name locked
Category locked
Locked

Purified enzymes for IVD and health applications

Funding Insights of Pentavalent

Pentavalent has successfully raised a total of $40.82K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $40.82 thousand completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Pentavalent

Pentavalent has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Bioinnovation Centre and Startup Karnataka.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Govt backed startup incubator focused on the Life Science sector
Locked Locked Locked
Support for startups in Karnataka is delivered through policies, funding, and networking services.
Locked Locked Locked
Premium access

Investor details for Pentavalent

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Pentavalent

Investments
Premium access

Investment portfolio details for Pentavalent

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Pentavalent

Premium access

Detailed financials for Pentavalent

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Pentavalent Comparisons

Pentavalent Primary company
Description
Vaccines and research services for infectious diseases are p...
Location
Bengaluru, India
Founded Year
2015
Annual Revenue
$241.41 K (USD)
Net Profit
$20.74 K (USD)
EBITDA
$31.07 K (USD)
Employees
Not available
Premium access

Peer comparison for Pentavalent

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Pentavalent

Pentavalent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Chimerix, HOOKIPA Pharma and Novavax, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
mRNA-based therapeutics for diseases including cancer and infections are developed.
Locked Locked Locked
Clinical diagnostics and drug discovery for immune diseases are provided.
Locked Locked Locked
Antiviral oral therapeutics are developed for infectious diseases and cancers.
Locked Locked Locked
Developer of immunotherapies for the treatment of infectious diseases and cancer
Locked Locked Locked
Novel vaccines are developed using nanoparticle and matrix adjuvant technology.
Locked Locked Locked
Developer of novel protein-based therapeutics using machine learning and biological engineering
Premium access

Detailed competitors of Pentavalent

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Pentavalent

Premium access

Complete news archive for Pentavalent

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pentavalent

Pentavalent was founded in 2015 and raised its 1st funding round 2 years after it was founded.

Pentavalent is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Pentavalent is a funded company, having raised a total of $40.82K across 2 funding rounds to date.

Annual revenue of Pentavalent is $241.41K as on Mar 31, 2023.

Pentavalent was founded in 2015 in Bengaluru, India, within the biotechnology sector. Research services are delivered in proteomics, genomics, molecular techniques, antibody generation, microbial studies, cell culture, computational assistance, and preclinical areas. Vaccines and diagnostics for infectious diseases are developed as part of core operations.

Pentavalent's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.

Pentavalent offers Antibodies, Antigens, Cytokines, and Enzymes.

Pentavalent has 2 investors. Key investors include Bioinnovation Centre, and Startup Karnataka.

The valuation of Pentavalent is $806.3K as of Oct 2020.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available